As <em>The Wall Street Journal</em> reports, the Irvine, CA-based Allergan is the latest apple of deal-happy Valeant's eye. And allied with activist investor Bill Ackman–who recently flew under the radar to amass a 9.7% Allergan share–it might just have the heft to pull off a pickup, with or without Allergan's blessing.
written on 22.04.2014
Valeant touts quick cost cuts in $45B hostile bid for Allergan
